Amgen Inc. Reports Strong Second‑Quarter Results and Raises Guidance

Amgen Inc. (NASDAQ: AMGN) released its second‑quarter 2026 financial results on August 4, 2026. The biotechnology company reported a net income of $2.375 billion, an increase from the prior year, and announced that sales of its flagship drug Repatha rose 37 %. The earnings beat Wall Street expectations and prompted the company to lift its full‑year profit and revenue forecasts.

Following the earnings announcement, the stock price moved into a new trading range, with a close of $407.83 on August 4 and a 52‑week high of $416.22. The 52‑week low, recorded on September 25, 2025, was $269.77. Amgen’s market capitalization stands at approximately $204.7 billion and its price‑to‑earnings ratio is 26.87.

Analyst Response

In the days after the earnings release, several analysts updated their outlooks:

  • TD Cowen raised its price target from $420.00 to $452.00 in a research note published on August 6.
  • A study of analyst recommendations at major brokerages placed Amgen as the #17 pick out of 30 Dow‑30 stocks, according to data released by Nasdaq on August 4.
  • German‑language financial outlets noted that Amgen’s guidance was “optimistic again” and that investors were pleased with the company’s performance.

Operational Highlights

  • Repatha – The drug’s sales jumped 37 % in Q2, contributing significantly to the company’s revenue growth.
  • Profitability – Net income increased year‑on‑year, supporting the upgraded earnings guidance.
  • Data Breach Investigation – A separate PRNewswire release on August 3 reported that Amgen was under investigation for a data breach involving unauthorized access to patient records. The company has engaged legal counsel Schubert Jonckheer & Kolbe LLP to investigate the incident.

Market Context

Amgen’s earnings announcement came amid broader market activity:

  • The Dow reached a record high on August 5, driven by gains in technology stocks such as Nvidia.
  • U.S. equity indices experienced a brief rally before encountering downside pressure later in the day.
  • International market reports noted significant volatility in commodity prices and a strong performance in the Chinese A‑share market.

Summary

Amgen Inc. delivered robust second‑quarter earnings, with a notable increase in Repatha sales and a 37 % revenue lift for the drug. The company’s upward revision of its full‑year guidance and the subsequent analyst upgrades reflect confidence in its financial trajectory. While the data‑breach investigation remains unresolved, the company’s core business continues to demonstrate strong growth and profitability within the biotechnology sector.